Edition:
United Kingdom

Galapagos NV (GLPG.AS)

GLPG.AS on Amsterdam Stock Exchange

77.69EUR
15 Dec 2017
Change (% chg)

€6.37 (+8.93%)
Prev Close
€71.32
Open
€76.00
Day's High
€78.39
Day's Low
€74.55
Volume
1,505,291
Avg. Vol
414,510
52-wk High
€89.75
52-wk Low
€54.64

Select another date:

Fri, Dec 15 2017

BRIEF-Galapagos Exercises Co-Promotion Option For Filgotinib

* SAID ON THURSDAY IT WILL OPT-IN ON CO-PROMOTION OF FILGOTINIB WITH COLLABORATION PARTNER GILEAD SCIENCES IN EIGHT EUROPEAN COUNTRIES, SHOULD FILGOTINIB BE APPROVED FOR COMMERCIAL SALE

BRIEF-Galapagos To Enter NASDAQ Biotech Index Effective Dec 18‍​

* TO ENTER NASDAQ BIOTECH INDEX EFFECTIVE DEC 18‍​ Source text: http://bit.ly/2jM5AGV Further company coverage: (Gdynia Newsroom)

BRIEF-Galapagos NV ‍announces share capital increase arising from warrant exercises​

* ‍Announces a share capital increase arising from warrant exercises​

BRIEF-Galapagos NV reports Q3 loss of ‍1.75​ euro per share

* Galapagos NV qtrly ‍revenues 106.4 million euro versus 65 million euro​

BRIEF-Galapagos & Morphosys announce Phase 1 results with joint investigational antibody program MOR106

* Co, Morphosys report first promising signs of clinical activity in phase 1 study with IL-17C antibody MOR106 in Atopic Dermatitis patients

BRIEF-Galapagos says GLPG1690 halts disease progression in IPF patients in mid-stage trial

* GLPG1690 halts disease progression in IPF patients in Flora phase 2A trial

BRIEF-Galapagos H1 revenues up at EUR 73.0 mln

* ANNOUNCED ON THURSDAY H1 REVENUES EUR 73.0 MLN VS EUR 48.8 MLN YEAR AGO

BRIEF-Servier announces it has exercised option to develop osteoarthritis molecule from Galapagos

* SERVIER ANNOUNCES IT HAS EXERCISED OPTION TO DEVELOP NOVEL OSTEOARTHRITIS MOLECULE GLPG1972/S201086 FROM GALAPAGOS NV, OBTAINING GLOBAL COMMERCIAL RIGHTS OUTSIDE THE U.S.

BRIEF-Galapagos announces new phase 2 study with filgotinib

* NEW PHASE 2 STUDY WITH FILGOTINIB IN NON-INFECTIOUS UVEITIS‍​

BRIEF-Galapagos announces successful completion of Phase 1

* GALAPAGOS' RESEARCH AND DEVELOPMENT UPDATE 2017: RAPIDLY ADVANCING OUR PRODUCT CANDIDATES

Select another date: